中文

← All funding rounds

Octopath AI

EuropeBiology data and toolsLondon, England, United KingdomPrivate

Website · octopath.ai ↗

A UCL spin-out whose two models read routine pathology slides cell by cell: Kraken on H&E stains, trained on 14.1 million labelled cells across 14 tissue and cancer types, and Nemo on immunohistochemistry stains, scoring markers such as Ki67, PD-L1, ER/PR and HER2.

Disclosed total-
Rounds on record1
Latest round£1M seed, with a £500k Innovate UK grant matched to it: £1.5M in allSeed · 2026-11-02
Last stated valuationNone stated
Investors named1
Research on recordNone yet

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date2027Seed
Closed roundNot on the dollar scale (a range, or no rate)

No research by this company is on the record yet.

Rounds and research, on one timeline

  1. 2026-11-02Seed
    Round

    £1M seed, with a £500k Innovate UK grant matched to it: £1.5M in all

    For: clinical evaluation, product development and work towards regulatory approval

    Toward the clinicModels and platform

    UCL's announcement of 2 November (https://www.ucl.ac.uk/news/2026/nov/ucl-spinout-octopathai-aims-develop-tool-precision-cancer-treatment) refuses automated readers; read through Startupmag's report of it the same day, which carries its figures and quotes. The announcement gives £1.5M in total including the £500k grant unlocked on a matched basis, so the private seed is £1M; valuation and close date are not disclosed.

    Lead · Twin Path Ventures

    Announced by the company · startupmag.co.uk ↗On the timeline →

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

Its investors also backed

Other companies on this page whose rounds name the same investor.